From: Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals
 | CSF-cohort | PET-cohort | ||||||
---|---|---|---|---|---|---|---|---|
Baseline characteristics | A\(\beta\)-Converter | A\(\beta\)-Stable | Auxiliary data | Regression-cohort | A\(\beta\)-Converter | A\(\beta\)-Stable | Auxiliary data | Regression-cohort |
Sample size (N) | 52 (32%) | 110 (68%) | 78 | 253 | 53 (23%) | 178 (77%) | 82 | 385 |
ADNI1/ADNIGO/ADNI2/ADNI3 | 15/6/30/1 | 25/18/67/0 | 27/7/41/3 | 81/35/137/0 | 0/7/44/2 | 0/31/140/7 | 0/8/66/8 | 0/69/308/8 |
Age, years | 73.7 (7.9) | 71.4 (7.0) | 73.11 (6.7) | 72.1 (6.7) | 71.9 (6.9) | 70.2 (6.8) | 72.4 (7.1) | 71.4 (6.7) |
Sex, M/F | 25/27 | 59/51 | 38/40 | 138/115 | 26/27 | 92/86 | 38/44 | 194/191 |
Education, years | 16.9 (2.4) | 16.3 (2.6) | 16.1 (2.8) | 16.3 (2.7) | 16.6 (2.5) | 16.7 (2.5) | 16.2 (2.7) | 16.4 (2.5) |
APOE4 (0/1/2) | 32/15/5 | 96/14/0 | 32/36/10 | 163/73/17 | 32/18/3 | 149/26/3 | 40/36/6 | 245/116/tr24 |
CN/SMC/EMCI/LMCI | 16/5/12/19 | 51/12/26/21 | 19/6/18/35 | 95/18/62/78 | 28/7/13/5 | 65/24/64/25 | 17/20/28/17 | 123/57/139/66 |
A\(\beta\)42 (CSF-cohort)/global SUVR (PET-cohort) | 1036.4 (182.2) | 1791.4 (526.4) | 754.4 (54.8) | 1196.3 (661.5) | 1.05 (0.04) | 1.00 (0.04) | 1.18 (0.04) | 1.44 (0.20) |